Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA has approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma.
Efficacy was evaluated in KEYNOTE-868/NRG-GY018 (ClinicalTrials.gov. Identifier: NCT03914612), a multicenter, randomized, double-blind, placebo-controlled trial enrolling 810 patients with advanced